ETF Holdings Breakdown of RXRX

Stock Name	Recursion Pharmaceuticals Inc
Ticker	RXRX(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US75629V1044

News associated with RXRX

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $7.00 Average Price Target from Analysts: Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) have been given a consensus recommendation of “Hold” by the six research firms that are presently covering the stock, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month […] - 2025-06-27 05:10:58
Morgan Stanley Has Lowered Expectations for Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price: Recursion Pharmaceuticals (NASDAQ:RXRX – Get Free Report) had its target price cut by analysts at Morgan Stanley from $8.00 to $5.00 in a report released on Monday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Morgan Stanley’s target price indicates a potential upside of 3.31% from the stock’s previous close. Several […] - 2025-06-18 05:50:50
Azzad Asset Management Inc. ADV Raises Stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX): Azzad Asset Management Inc. ADV boosted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 21.6% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 16,811 shares of the company’s stock after buying an additional 2,982 shares during the period. […] - 2025-06-16 08:54:48
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Purchased by Integrated Advisors Network LLC: Integrated Advisors Network LLC boosted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 17.1% during the 1st quarter, Holdings Channel reports. The fund owned 20,603 shares of the company’s stock after acquiring an additional 3,015 shares during the quarter. Integrated Advisors Network LLC’s holdings in Recursion Pharmaceuticals were worth $109,000 as of […] - 2025-06-16 08:05:20
California State Teachers Retirement System Acquires 54,449 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX): California State Teachers Retirement System boosted its stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 30.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 231,535 shares of the company’s stock after acquiring an additional 54,449 shares during the quarter. […] - 2025-06-09 07:43:00
Squarepoint Ops LLC Takes Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX): Squarepoint Ops LLC bought a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 80,421 shares of the company’s stock, valued at approximately $544,000. A number of other institutional investors also […] - 2025-06-04 08:48:48
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives Average Rating of “Hold” from Analysts: Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) have earned a consensus rating of “Hold” from the six research firms that are covering the company, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective […] - 2025-05-30 05:10:57
Two Sigma Advisers LP Has $3.05 Million Stock Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX): Two Sigma Advisers LP trimmed its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 7.8% in the 4th quarter, Holdings Channel.com reports. The fund owned 451,745 shares of the company’s stock after selling 38,155 shares during the quarter. Two Sigma Advisers LP’s holdings in Recursion Pharmaceuticals were worth $3,054,000 as of […] - 2025-05-27 08:57:01
Man Group plc Makes New $479,000 Investment in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX): Man Group plc bought a new position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) in the 4th quarter, HoldingsChannel reports. The fund bought 70,802 shares of the company’s stock, valued at approximately $479,000. Several other hedge funds also recently bought and sold shares of RXRX. Private Trust Co. NA purchased a new […] - 2025-05-27 07:59:05
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Sold by Cresset Asset Management LLC: Cresset Asset Management LLC lessened its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 64.6% during the fourth quarter, HoldingsChannel reports. The fund owned 25,029 shares of the company’s stock after selling 45,663 shares during the period. Cresset Asset Management LLC’s holdings in Recursion Pharmaceuticals were worth $169,000 at the end […] - 2025-05-19 08:02:51
Price T Rowe Associates Inc. MD Raises Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX): Price T Rowe Associates Inc. MD raised its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 17.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 131,990 shares of the company’s stock after acquiring an additional […] - 2025-05-12 08:10:49
Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Down 5.4% After Earnings Miss: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report)’s stock price fell 5.4% on Tuesday following a weaker than expected earnings announcement. The stock traded as low as $4.45 and last traded at $4.51. 7,052,787 shares were traded during trading, a decline of 44% from the average session volume of 12,553,666 shares. The stock had previously […] - 2025-05-08 05:42:51
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Receives $8.20 Consensus Price Target from Analysts: Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) have received a consensus recommendation of “Hold” from the six brokerages that are currently covering the firm, Marketbeat.com reports. Four analysts have rated the stock with a hold recommendation and two have assigned a buy recommendation to the company. The average 12 month price target […] - 2025-05-08 05:04:58
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 9.6% on Disappointing Earnings: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) shares dropped 9.6% on Monday following a dissappointing earnings announcement. The company traded as low as $5.23 and last traded at $5.16. Approximately 9,031,494 shares were traded during trading, a decline of 28% from the average daily volume of 12,478,559 shares. The stock had previously closed at […] - 2025-05-07 05:54:42
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Gap Down on Disappointing Earnings: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) gapped down prior to trading on Monday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $5.70, but opened at $5.49. Recursion Pharmaceuticals shares last traded at $5.33, with a volume of 5,427,114 shares. The company reported ($0.50) earnings per share […] - 2025-05-06 05:10:57
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Shares Bought by Mariner LLC: Mariner LLC boosted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 32.9% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 111,063 shares of the company’s stock after buying an additional 27,499 shares during the quarter. […] - 2025-04-29 07:56:57
Barclays PLC Has $4.28 Million Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX): Barclays PLC trimmed its position in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 9.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 633,125 shares of the company’s stock after selling 64,307 shares during the period. Barclays PLC’s holdings […] - 2025-04-28 07:59:05
JPMorgan Chase & Co. Sells 119,024 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX): JPMorgan Chase & Co. trimmed its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 10.1% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 1,057,167 shares of the company’s stock after selling 119,024 shares during the period. JPMorgan Chase & Co.’s holdings in Recursion Pharmaceuticals were worth $7,146,000 at the end of […] - 2025-04-17 07:27:22
Geode Capital Management LLC Has $41.16 Million Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX): Geode Capital Management LLC boosted its holdings in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 12.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 6,087,149 shares of the company’s stock after acquiring an additional 655,238 shares during the quarter. Geode […] - 2025-04-16 08:14:51
Raymond James Financial Inc. Invests $609,000 in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX): Raymond James Financial Inc. acquired a new stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) in the 4th quarter, HoldingsChannel reports. The institutional investor acquired 90,107 shares of the company’s stock, valued at approximately $609,000. Several other institutional investors and hedge funds also recently added to or reduced their stakes in RXRX. Decker Retirement […] - 2025-04-07 07:51:05
Swiss National Bank Boosts Holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX): Swiss National Bank grew its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 36.3% in the 4th quarter, Holdings Channel reports. The institutional investor owned 486,700 shares of the company’s stock after purchasing an additional 129,600 shares during the quarter. Swiss National Bank’s holdings in Recursion Pharmaceuticals were worth $3,290,000 as of its […] - 2025-03-27 08:12:59
RXRX Quantitative Stock Analysis - Benjamin Graham: Below is Validea's guru fundamental report for RECURSION PHARMACEUTICALS INC (RXRX). Of the 22 guru strategies we follow, RXRX rates highest using our Value Investor model based on the published strategy of Benjamin Graham. This deep value methodology screens for stocks that hav - 2025-03-18 18:58:04
Private Advisor Group LLC Purchases 16,008 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX): Private Advisor Group LLC increased its stake in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 103.8% in the fourth quarter, Holdings Channel reports. The firm owned 31,427 shares of the company’s stock after purchasing an additional 16,008 shares during the period. Private Advisor Group LLC’s holdings in Recursion Pharmaceuticals were worth $212,000 as of […] - 2025-03-07 08:41:03
IFP Advisors Inc Purchases 7,455 Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX): IFP Advisors Inc lifted its position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 170.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 11,831 shares of the company’s stock after acquiring an additional 7,455 shares during the quarter. IFP […] - 2025-03-06 10:45:49
Recursion Pharmaceuticals (NASDAQ:RXRX) Shares Down 5.3% After Earnings Miss: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Get Free Report) was down 5.3% during mid-day trading on Monday following a weaker than expected earnings announcement. The stock traded as low as $7.07 and last traded at $7.11. Approximately 8,143,605 shares were traded during trading, a decline of 68% from the average daily volume of 25,618,289 shares. The […] - 2025-03-04 06:55:13
Atria Wealth Solutions Inc. Takes $75,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX): Atria Wealth Solutions Inc. purchased a new stake in shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) during the 4th quarter, Holdings Channel.com reports. The institutional investor purchased 11,123 shares of the company’s stock, valued at approximately $75,000. A number of other institutional investors also recently bought and sold shares of the stock. Allspring […] - 2025-03-03 08:25:03
Pre-Market Most Active for Feb 28, 2025 : NVDA, TSLL, IBIT, SMCI, RXRX, SQQQ, FUBO, NIO, BABA, QBTS, ACHR, IONQ: The NASDAQ 100 Pre-Market Indicator is up 27.28 to 20,578.23. The total Pre-Market volume is currently 108,919,621 shares traded.The following are the most active stocks for the pre-market session: NVIDIA Corporation (NVDA) is -3.14 at $117.01, with 14,573,938 shares traded. As - 2025-02-28 13:29:59
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Stock Position Raised by Global Retirement Partners LLC: Global Retirement Partners LLC boosted its holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX – Free Report) by 31.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 31,297 shares of the company’s stock after acquiring an additional 7,500 shares during the period. Global Retirement […] - 2025-02-26 09:54:55
Pre-Market Most Active for Feb 19, 2025 : NIVF, INTC, TSLL, SMCI, NVDA, RXRX, NIO, SAN, BBAI, STM, ACHR, IONQ: The NASDAQ 100 Pre-Market Indicator is down -42.83 to 22,121.78. The total Pre-Market volume is currently 209,799,309 shares traded.The following are the most active stocks for the pre-market session: NewGenIvf Group Limited (NIVF) is +1.19 at $3.38, with 1,474,660 shares traded - 2025-02-19 09:31:20
Why Recursion Pharmaceuticals Stock Is Soaring Today: Shares of Recursion Pharmaceuticals (NASDAQ: RXRX) had soared by 15.8% as of 12:06 p.m. ET on Friday. Did the clinical-stage biotech company report great news? Nope. Instead, the stock's gains appeared to be driven by moves made by Nvidia (NASDAQ: NVDA). - 2025-02-14 17:07:40

RXRX institutional holdings

The following institutional investment holdings of RXRX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-06-26 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 163,332 USD 881,993

2025-06-26 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 115,349 USD 622,885

2025-06-26 IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc)) 494,723 USD 2,671,504

2025-06-26 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 199,445 USD 1,077,003

2025-06-26 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 199,445 USD 1,077,003

2025-06-26 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 7,801 USD 42,125

Total = 1,180,095 USD 6,372,513
Book value of shares is calculated on the adjusted close price of each day (row).

Date	ETF ISIN/Name	Num Shares	Book value
2025-06-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	163,332	USD 881,993
2025-06-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	115,349	USD 622,885
2025-06-26	IE00BYZK4776 (iShares Healthcare Innovation UCITS ETF USD (Acc))	494,723	USD 2,671,504
2025-06-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	199,445	USD 1,077,003
2025-06-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	199,445	USD 1,077,003
2025-06-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	7,801	USD 42,125
Total =	1,180,095	USD 6,372,513

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.